Literature DB >> 17481749

A meta-analysis of randomised controlled trials assessing drug-eluting stents and vascular brachytherapy in the treatment of coronary artery in-stent restenosis.

Lisa N Oliver1, Petra G Buttner, Helen Hobson, Jonathan Golledge.   

Abstract

OBJECTIVE: We undertook a meta-analysis of randomised trials assessing the outcome of vascular brachytherapy (VBT) or DES for the treatment of coronary artery ISR. METHODS AND
RESULTS: Studies utilising DES or VBT for ISR were identified by a systematic search. Data was pooled and combined overall effect measures were calculated for a random effect model in terms of deaths, myocardial infarctions, revascularisation, binary restenosis, mean late luminal loss and major adverse cardiac events (MACE). Fourteen eligible studies (3103 patients) were included. Neither therapy had any effect on mortality or myocardial infarction rate. VBT reduced the rate of revascularisation (RR 0.59, 95%CI 0.50-0.68), MACE (RR 0.58, 95%CI 0.51-0.67), binary restenosis (RR 0.51, 95%CI 0.44-0.59) and late loss (-0.73 mm, 95%CI -0.91 to -0.55 mm) compared to balloon angioplasty and selective bare metal stents (BMS) alone at intermediate follow-up and MACE (RR 0.72, 95%CI 0.61-0.85) at long-term follow-up. DES reduced the rate of revascularisation (OR 0.51, 95% CI 0.36-0.71), MACE (OR 0.55, 95% CI 0.39-0.79) and binary restenosis (OR 0.57, 95% CI 0.40-0.81) compared to VBT but follow-up was limited to 9 months.
CONCLUSIONS: VBT improves the long-term outcome of angioplasty compared with BMS alone in the treatment of ISR. DES appears to provide similar results to that of VBT during short-term follow-up.

Entities:  

Mesh:

Year:  2007        PMID: 17481749      PMCID: PMC2435504          DOI: 10.1016/j.ijcard.2007.03.132

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  39 in total

Review 1.  Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses.

Authors:  D Moher; D J Cook; S Eastwood; I Olkin; D Rennie; D F Stroup
Journal:  Lancet       Date:  1999-11-27       Impact factor: 79.321

2.  The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials.

Authors:  D Moher; K F Schulz; D G Altman
Journal:  Lancet       Date:  2001-04-14       Impact factor: 79.321

Review 3.  The ARTISTIC and ARREST trials.

Authors:  A Durairaj; D P Faxon
Journal:  J Invasive Cardiol       Date:  2000-01       Impact factor: 2.022

4.  Intracoronary gamma-radiation therapy after angioplasty inhibits recurrence in patients with in-stent restenosis.

Authors:  R Waksman; R L White; R C Chan; B G Bass; L Geirlach; G S Mintz; L F Satler; R Mehran; P W Serruys; A J Lansky; P Fitzgerald; B Bhargava; K M Kent; A D Pichard; M B Leon
Journal:  Circulation       Date:  2000-05-09       Impact factor: 29.690

5.  Usefulness of intracoronary brachytherapy for in-stent restenosis with a 188Re liquid-filled balloon.

Authors:  H Schühlen; N Eigler; J S Whiting; R Haubner; J Hausleiter; J Dirschinger; A Kastrati; M Schwaiger; A Schömig
Journal:  Am J Cardiol       Date:  2001-02-15       Impact factor: 2.778

6.  Rotational atherectomy does not reduce recurrent in-stent restenosis: results of the angioplasty versus rotational atherectomy for treatment of diffuse in-stent restenosis trial (ARTIST).

Authors:  Juergen vom Dahl; Ulrich Dietz; Philipp K Haager; Sigmund Silber; Luigi Niccoli; Hans Juergen Buettner; Francois Schiele; Martyn Thomas; Philippe Commeau; David R Ramsdale; Eulogio Garcia; Christian W Hamm; Rainer Hoffmann; Thorsten Reineke; Heinrich G Klues
Journal:  Circulation       Date:  2002-02-05       Impact factor: 29.690

7.  Intravascular gamma radiation for in-stent restenosis in saphenous-vein bypass grafts.

Authors:  Ron Waksman; Andrew E Ajani; R Larry White; Rosanna C Chan; Lowell F Satler; Kenneth M Kent; Augusto D Pichard; Ellen E Pinnow; Anh B Bui; Steven Ramee; Paul Teirstein; Joseph Lindsay
Journal:  N Engl J Med       Date:  2002-04-18       Impact factor: 91.245

8.  Inhibition of restenosis with beta-emitting radiotherapy: Report of the Proliferation Reduction with Vascular Energy Trial (PREVENT).

Authors:  A E Raizner; S N Oesterle; R Waksman; P W Serruys; A Colombo; Y L Lim; A C Yeung; W J van der Giessen; L Vandertie; J K Chiu; L R White; P J Fitzgerald; G L Kaluza; N M Ali
Journal:  Circulation       Date:  2000-08-29       Impact factor: 29.690

9.  Three-year clinical and angiographic follow-up after intracoronary radiation : results of a randomized clinical trial.

Authors:  P S Teirstein; V Massullo; S Jani; J J Popma; R J Russo; R A Schatz; E M Guarneri; S Steuterman; K Sirkin; D A Cloutier; M B Leon; P Tripuraneni
Journal:  Circulation       Date:  2000-02-01       Impact factor: 29.690

10.  Use of localised intracoronary beta radiation in treatment of in-stent restenosis: the INHIBIT randomised controlled trial.

Authors:  Ron Waksman; Albert E Raizner; Alan C Yeung; Alexandra J Lansky; Lynn Vandertie
Journal:  Lancet       Date:  2002-02-16       Impact factor: 79.321

View more
  3 in total

1.  Network meta-analyses on in-stent restenosis treatment: dealing with complexity to clarify efficacy and safety.

Authors:  Fernando Alfonso; Fernando Rivero
Journal:  J Thorac Dis       Date:  2015-10       Impact factor: 2.895

2.  In-Stent Restenosis: Pathophysiology and Treatment.

Authors:  Patrick M Looser; Luke K Kim; Dmitriy N Feldman
Journal:  Curr Treat Options Cardiovasc Med       Date:  2016-02

3.  Targeted inhibitory effect of Lenti-SM22alpha-p27-EGFP recombinant lentiviral vectors on proliferation of vascular smooth muscle cells without compromising re-endothelialization in a rat carotid artery balloon injury model.

Authors:  Liang Jing; Wenlong Wang; Shuangshuang Zhang; Minjie Xie; Daishi Tian; Xiang Luo; Daowen Wang; Qin Ning; Jiagao Lü; Wei Wang
Journal:  PLoS One       Date:  2015-03-11       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.